Abstract: The present invention relates to a dispensing system for spraying a liquid/gas mixture, the system including a dispenser and a holder in which the dispenser is held, the dispenser including a container that is adapted for holding therein a liquid phase and a gas phase that is at a pressure of 2 bar or greater and is in direct contact with the liquid phase. The dispensing system may be used in a first orientation and a second orientation, wherein the ratio of liquid to gas in the sprayed mixture is different depending on the orientation of the system during spraying.

Abstract: The present invention relates to a dispensing system for spraying a liquid/gas mixture, the system comprising a dispenser and a holder in which the dispenser is held, the dispenser comprising a container that is adapted for holding therein a liquid phase and a gas phase that is at a pressure of 2 bar or greater and is in direct contact with the liquid phase. The dispensing system may be used in a first orientation and a second orientation, wherein the ratio of liquid to gas in the sprayed mixture is different depending on the orientation of the system during spraying.

Abstract: The invention relates to a dispensing system for use in cryogenic skin treatment that is capable of targeted delivery of a cryogen at a high rate, thereby achieving rapid freezing of targeted skin tissue. The dispensing system of the present invention uses a cryogen that contains dimethyl ether and is designed to deliver the cryogen in an accurate and very effective manner.

Abstract: An applicator for applying cryogenic fluid to a treatment area is described, the applicator comprising: a reservoir (12) configured to contain a cryogenic fluid comprising a gas phase (G) and a liquid phase (L). A nozzle (20) extends from a proximal end arranged in fluid communication with the reservoir (12) to an open distal end (21) for application of fluid to a treatment area. An actuatable valve is provided to selectively allow a flow of cryogenic fluid from the reservoir (12) through the distal end of the nozzle (20). A spacer (14) extends distally beyond the distal end (21) of the nozzle (20), the spacer (14) comprising a skin contacting surface (14a) at its distal end. A porous material (16) is provided between the distal end (21) of the nozzle (20), at least between the open end of the nozzle and the skin contacting surface of the spacer.

Abstract: The invention provides a method for preparing tissue-adhesive sheets that may suitably be applied as an implantable haemostatic or sealing construct during surgical procedures, said method comprising: providing a fibrous sheet comprising a three-dimensional interconnected interstitial space; providing reactive polymer particles comprising a water-soluble electrophilic polymer carrying at least 3 reactive electrophilic groups that are capable of reacting with amine groups in blood under the formation of a covalent bond; placing the fibrous sheet and the reactive polymer particles between two electrodes; simultaneously subjecting the fibrous sheet and the reactive polymer particles to an electric field of 0.1 to 40 kV/mm to impregnate the interconnected interstitial space of the fibrous sheet with the reactive polymer particles.

Abstract: Provided herein is a method of treating an infectious disease by administering to a patient a pharmaceutical formulation dissolved in aqueous medium having at least one free fatty acid, or a derivative and/or a pharmaceutically acceptable salt of the same, where the free fatty acid has from 6 to 16 carbon atoms, at least one carboxylic acid or a pharmaceutically acceptable salt of the same, and/or at least one carbohydrate or a pharmaceutically acceptable salt of the same. The carbohydrate may be selected from a hydrogenated carbohydrate, a monosaccharide, a disaccharide, a polysaccharide or a combination of the same. The antimicrobial composition provides enhanced anti-adhesion and/or disinfecting properties. The composition may be formulated into a drink, gel or spray, suitable for treating or preventing the first stage in pathogenesis.

Abstract: The present invention relates to a method for administering water soluble physiologically active substances, said method comprising intranasally administering to a subject an aqueous composition comprising 0.001-25 wt. % of one or more fully dissolved physiologically active substances, the physiologically active substances having a water solubility in demineralized water of at least 15 mg/mL at 20° C. of, 0.01-10 wt. % nicotinamide, and at least 60 wt. % water. The invention also relates to a kit comprising said composition and to the use of nicotinamide as an enhancer of intranasal absorption of a physiologically active substance from an aqueous solution, wherein the aqueous solution further comprises 0.01-10 wt. % nicotinamide.

Abstract: The invention relates to a dispensing system for use in cryogenic skin treatment that is capable of targeted delivery of a cryogen at a high rate, thereby achieving rapid freezing of targeted skin tissue. The dispensing system of the present invention uses a cryogen that contains dimethyl ether and is designed to deliver the cryogen in an accurate and very effective manner.

Abstract: The present invention relates to a method for administering water soluble physiologically active substances, said method comprising intranasally administering to a subject an aqueous composition comprising 0.001-25 wt. % of one or more fully dissolved physiologically active substances, the physiologically active substances having a water solubility in demineralized water of at least 15 mg/mL at 20° C. of, 0.01-10 wt. % nicotinamide, and at least 60 wt. % water. The invention also relates to a kit comprising said composition and to the use of nicotinamide as an enhancer of intranasal absorption of a physiologically active substance from an aqueous solution, wherein the aqueous solution further comprises 0.01-10 wt. % nicotinamide.

Abstract: The present invention relates to a nebulizer, such as a spray can, for the topical application of a liquid and/or solid to a surface. The nebulizer is characterized by a valve comprising a mixing chamber designed for forming a colloidal mixture comprising a dispersed phase consisting of a liquid and/or a solid substance and a continuous phase consisting of a propellant gas before delivering the colloidal mixture to the nozzle. The invention also relates to a method for the topical cooling of the skin of a person or animal. In addition, the invention relates to various other uses of the device.

Abstract: The present invention relates to a nebulizer, such as a spray can, for the topical application of a liquid and/or solid to a surface. The nebulizer is characterized by a valve comprising a mixing chamber designed for forming a colloidal mixture comprising a dispersed phase consisting of a liquid and/or a solid substance and a continuous phase consisting of a propellant gas before delivering the colloidal mixture to the nozzle. The invention also relates to a method for the topical cooling of the skin of a person or animal. In addition, the invention relates to various other uses of the device.

Abstract: One aspect of the invention relates to a pharmaceutical dosage unit for sublingual, buccal, pulmonary or oral administration, said dosage unit having a weight of 20-500 mg and comprising 1-80 wt. % of a microgranulate that is distributed throughout a solid hydrophilic matrix; said microgranulate being characterized in that it: has a volume weighted average diameter of 5-100 m; contains at least 0.01 wt. %, preferably at least 0.1 wt. % of one or more water-insoluble pharmaceutically active substances; contains at least 10 wt. %, preferably at least 20 wt. % of an emulsifier component; and is capable of forming a micro-emulsion upon contact with saliva or water. The dosage units of the present invention achieve the inherent benefits of oral delivery while at the same time realizing a high transmucosal absorption rate of the cannabinoids contained therein.

Abstract: Provided herein is an antimicrobial composition having at least one free fatty acid or a derivative and/or a pharmaceutically acceptable salt thereof, wherein the free fatty acid has from 6 to 16 carbon atoms, at least one carboxylic acid or a pharmaceutically acceptable salt thereof and/or at least one carbohydrate or a pharmaceutically acceptable salt thereof, wherein the carbohydrate is selected from a hydrogenated carbohydrate, a monosaccharide, a disaccharide, a polysaccharide and combinations thereof. The antimicrobial composition provides enhanced anti-adhesion and/or disinfecting properties. The composition of the present invention can be formulated into a drink, gel or spray suitable for treating or preventing the first stage in pathogenesis.

Abstract: The present invention relates to ready-to-use sterile, alginate-based, aqueous compositions for medical use. More particularly, the invention relates to an aqueous composition for medical use that has been sterilized by heat sterilization and having a viscosity at 25° C. of at least 300 cP) (Helipath® T F spindle, 100 rpm at 25° C.), said composition having a pH in the range of 6.5-7.5; containing 0.5-10 wt. % of an alginate salt; and further containing 10-500 mM of one or more dissolved C2-C7 mono- or dicarboxylates that are optionally substituted with up to 2 hydroxyl groups. The alginate-based composition of the present invention has excellent storage stability and is easy to manufacture. The alginate-based aqueous compositions of the present invention can advantageously be used, for instance, to prevent adhesions between a healing trauma site and adjacent surrounding tissue. These compositions can further be used in implants or in pharmaceutical preparations for oral administration.

Abstract: The present invention relates to ready-to-use sterile, alginate-based, aqueous compositions for medical use. More particularly, the invention relates to an aqueous composition for medical use that has been sterilized by heat sterilization and having a viscosity at 25° C. of at least 300 cP) (Helipath® T F spindle, 100 rpm at 25° C.), said composition having a pH in the range of 6.5-7.5; containing 0.5-10 wt. % of an alginate salt; and further containing 10-500 mM of one or more dissolved C2-C7 mono- or dicarboxylates that are optionally substituted with up to 2 hydroxyl groups. The alginate-based composition of the present invention has excellent storage stability and is easy to manufacture. The alginate-based aqueous compositions of the present invention can advantageously be used, for instance, to prevent adhesions between a healing trauma site and adjacent surrounding tissue. These compositions can further be used in implants or in pharmaceutical preparations for oral administration.

Abstract: A device for treating pieces of a substrate at high pressure, piece by piece or in batches, with a treatment medium in the supercritical or near-critical state, includes a first pressure chamber, a pipe system for supplying and discharging the treatment medium, to and from the pressure chamber under high pressure and an electric motor, which is fixed to the housing in the first pressure chamber or in a second pressure chamber coupled to the first pressure chamber under the high pressure, for driving an actuator to carry out a mechanical action in the treatment medium. The electric motor is in this case open to the treatment medium and is disposed and designed to be accessible to the treatment medium, in such a manner that during the treatment of a substrate the treatment medium flows through and around the electric motor.

Abstract: One aspect of the present invention relates to a granulate having a volume weighted mean diameter of 1-200 m and containing: at least 0.1 wt. % of a pharmaceutically active substance; at least 10 wt. % of emulsifier 0-89.9 wt. % of a water-dispersible saccharide; the combination of the pharmaceutically active substance, the emulsifier and the water-dispersible saccharide together representing at least 60 wt. % of the granulate; wherein the granulate is monophasic or wherein the granulate comprises a dispersed phase containing the pharmaceutically active substance, said dispersed phase having a volume weighted mean diameter of less than 300 nm. Another aspect of the invention relates to a process for the preparation of said granulate containing a pharmaceutically active substance, which process employs.

Abstract: One aspect of the invention relates to a pharmaceutical dosage unit for sublingual, buccal, pulmonary or oral administration, said dosage unit having a weight of 20-500 mg and comprising 1-80 Wt. % of a microgranulate that is distributed throughout a solid hydrophilic matrix; said microgranulate being characterised in that it: has a volume weighted average diameter of 5-100 m; contains at least 0.01 wt. %, preferably at least 0.1 wt. % of one or more water-insoluble pharmaceutically active substances; contains at least 10 wt. %, preferably at least 20 wt. % of an emulsifier component; and is capable of forming a micro-emulsion upon contact with saliva or water. The dosage units of the present invention achieve the inherent benefits of oral delivery whilst at the same time realising a high transmucosal absorption rate of the cannabinoids contained therein.

Abstract: The invention discloses a method for preparing a powder from an aqueous liquid which comprises colloidal particles. The method is based on the use of dense-phase extraction media, i.e. near-critical or supercritical fluids. The powder obtained through the method can be reconstituted with an appropriate aqueous liquid to yield a colloidal dispersion. The method is particularly useful for drying and stabilising aqueous colloidal dispersions comprising an active compound, such as a drug substance.